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NANOCARRIER THERAPY FOR TREATING 
INVASIVE TUMORS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a national phase application oflnterna-
tional Patent Application PCT/US2010/031914 filed 21 Apr. 
2010, which claims priority to U.S. Provisional Application 
Ser. No. 61/171,745 filed 22 Apr. 2009, which applications 
are hereby incorporated by this reference in their entireties. 
FIELD OF THE INVENTION 
This invention relates in general to the field of anti-cancer 
therapeutics, and more particularly, to the use ofliposomes in 
the diagnosis and treatment of invasive tumors such as glio-
mas. 
BACKGROUND OF THE INVENTION 
Invasiveness of brain tumors is a major reason for poor 
prognosis after diagnosis. Unfortunately, there is a lack of 
available chemotherapeutic agents that negatively impact 
invasive gliomas. Additionally, gliomas present a difficult 
drug delivery paradigm due to the difficulty in transporting 
drugs across the blood-brain barrier. 
Malignant glioma, also known as glioblastoma multiforme 
(GBM), is a highly infiltrative form of brain tumor with a 
five-year survival rate of 2%, characterized by diffuse cell 
spread within the tumor and into the surrounding brain cre-
ating an ill-defined tumor border. Primary treatment options 
for include surgical final IB concentration of7-8 mg/ml resec-
tion, radiation, and chemotherapy. The rate of recurrence is 
high, and the average survival time post resection surgery is 
18 months. 
Novel therapeutics against cancer include more specific 
agents to attributes of tumor behavior including anti-angio-
genics, antihypoxics, and anti-invasives. Several anti-inva-
sive agents have shown promise in vitro for stopping tumor 
invasion and metastasis. These agents have not been tested in 
vivo due to limitations in delivery and dose accumulation at 
distant tumor sites. 
It would be advantageous to provide new drugs and drug 
delivery systems to target glioma invasion in vivo. The 
present invention provides such compositions, and methods 
for their use. 
SUMMARY OF THE INVENTION 
Compositions and methods fortreating cancer, particularly 
cancer characterized by the presence of invasive tumors, are 
disclosed. Although the compositions can be used generally 
2 
aliphatic side chains of a length of at least 16 carbons, and 
containing imipramine blue, or a pharmaceutically accept-
able salt thereof, sufficient to preferentially deliver (i.e., tar-
get) a quantity of the imipramine blue to the tumor. Vesicle 
diameter can be measured, for example, by dynamic light 
scattering using a helium-neon 100 mW NEC gas laser and a 
Malvern K7027 correlator, ideally with at least two or three 
measurements made for each for each size determination. 
The expression "chemically pure phospholipids" is meant 
10 to define phospholipids which are essentially free of delete-
rious detergent moieties and impurities which cause aggre-
gation of small unilamellar vesicles (SUVs) formed there-
from, and which are more than 97% pure. 
Preferably, the liposomes have a diameter predominantly 
15 of from about 50 to about 160 nm, are essentially neutral in 
charge, and incorporate phospholipids having a side chain 
length of from 16 to 18 carbon atoms. More preferably, the 
liposomes are prepared from distearoyl phosphatidylcholine 
(DSPC) and include cholesterol (most preferably in an 
20 amount of from !Oto 50% of total lipid) as a vesicle stabilizer. 
Most preferably, the liposomes further comprise a pegylated 
phospholipid, such as DSPE-PEG. 
The method involves introducing into a patient's blood-
stream an amount of liposomes, of a size ofless than 200 nm 
25 (preferably unilamellar vesicles) and preferably character-
ized by being comprised of chemically pure synthetic phos-
pholipids, most preferably having aliphatic side chains of a 
length of at least 16 carbons, and containing imipramine blue, 
or a pharmaceutically acceptable salt or prodrug thereof, suf-
30 ficient to preferentially deliver (i.e., target) a quantity of the 
imipramine blue to the tumor. 
While not wishing to be bound by any particular theory as 
to the targeting of the liposomes to tumors, it appears that the 
liposomes pass through capillaries with increased permeabil-
35 ity (increased pore size) and can preferentially penetrate 
tumor tissue, relative to normal tissue. With respect to treating 
brain tumors, it is relevant to note that the liposomes cross the 
blood brain barrier and deliver the imipramine blue to the 
brain. It is also believed that the imipramine blue, once 
40 administered to the tumor site, inhibits both tumor invasion 
and tumor metastasis. However, imipramine blue can be 
administered at dosages at which it is anti-invasive, but not 
cytotoxic or anti-proliferative, and provides a dose-depen-
dent anti-invasive response against malignant gliomas. At 
45 elevated dosages, imipramine blue is both anti-invasive and 
cytotoxic. 
The imipramine blue can be combined with other conven-
tional anti-tumor agents, as well as diagnostic agents. Such 
additional agents can also be present in the liposomes, can be 
50 present in different liposomes, or can be co-administered via 
a different route. 
BRIEF DESCRIPTION OF THE DRAWINGS 
to treat a variety of cancers, in one embodiment, they are used 
specifically to treat brain tumors, and, more specifically, to 55 
treat invasive gliomas. 
FIG. la is a bar graph showing the effects of IB on cell 
growth in vitro, in terms of normalized cell viability. The bars 
shown are (from left to right) the cytotoxicity to RT2 cells 
(µg/ml), the proliferation ofRT2 cells (µg/ml), and astrocytes 
(5 (µg/ml). The data show that IB was anti-invasive at con-
centrations at which it was not particularly cytotoxic or anti-
proliferative. 
The compositions include imipramine blue, or a pharma-
ceutically acceptable salt or prodrug thereof, in a liposome 
appropriately sized and formulated to cross the blood-brain 
barrier. In one embodiment, the liposomes include a pegy- 60 
lated phospholipid in a sufficient amount to increase the cir-
culating half-life of the liposomes, to increase the amount of 
the encapsulated imipramine blue that can be administered. 
The liposomes (preferably unilamellarvesicles) have a size 
less than 200 nm as measured by dynamic light scattering, 65 
and preferably characterized by being comprised of chemi-
cally pure synthetic phospholipids, most preferably having 
FIG. lb is a bar graph showing the dose dependent effects 
ofIB on invasion using a Boyden Chamber Assay. The chart 
shows percent invasion relative to control, with the bars rep-
resenting control, and IB dosed at 0.01 µg/ml, 0.1 µg/ml, 1 
µg/ml, and 5 µg/ml. At concentrations above 20 µg/ml, IB was 
cytotoxic to cancer, and not just anti-invasive. 
US 9,220,682 B2 
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FIG. 2 is an illustration of a liposome including imipramine 
blue (also referred to herein as IE). The black dots within the 
walls of the liposome represent imipramine blue, and the 
"tails" on the outside of the liposome represent polyethylene 
glycol chains, which provide the liposome with "stealth" 5 
properties, such as an increased in vivo circulating half-life 
relative to liposomes that do not include polyethylene glycol 
chains. 
FIGS. 3a and 3b are photographs showing the tumor pro-
gression at Day 11 in Fischer 344 Rats using DAPI stain for 
10 
cell nuclei. 
FIG. 4 is a chart showing the results of an invasion assay at 
24 hours, showing invasion (%) over time (24 hours). The 
control shows 100 percent invasion, free imipramine blue 
("TB") showed around 60% invasion, and liposomal TB 
("lipo IE") showed around 70% invasion. 
FIG. S is a chart showing the pharmacokinetics of free 
versus encapsulated imipramine blue, in terms of plasma 
concentration (mg/ml) over time (hours). 
15 
FIGS. 6A and 6B are photomicrographs showing untreated 
tumors, with green showing healthy tumor cells and blue 20 
indicating cell nuclei for unhealthy tumor cells and normal 
brain structures. 
FIG. 7 is a chart showing the results ofin vitro combination 
ofDoxorubicin ("Dox") and imipramine blue ("IE") against 
RT2 glioma cells. Cells were quantified by metabolic assay 25 (CCK-8, Dojindo) and compared to starting cell concentra-
tions(%). Cells were treatedfor 2 hours with Dox or Dox+IE 
and media replaced. Cells were quantified at 48h (p=0.04) 
and 72h (p=0.05). Co-treatment increased cell death com-
pared to Dox alone. 
30 FIG. 8 is a series of three photographs of lymph nodes 
collected from rats given subcutaneous injections ofliposo-
mal IE. The nodes are tinted blue from the color of the drug, 
indicating that the drug was delivered. 
FIGS. 9A and 9B are photomicrographs showing the 
results of in vitro treatment ofRT2 glioma cells with IE. Cells 35 
were treated with ethanol (6A) or IE (6B) and stained for actin 
(red) and nuclei (blue). 
FIG. 10 is a photograph showing untreated (left) and nano-
IE treated (right) axial brain sections stained with DAPI for 
nuclei showing tumor size/contra-lateral invasion difference 40 
after treatment. 
FIGS. llA and llB are H&E tumor border images of 
untreated (SA) and nano-IE treated (SB), showing the differ-
ence between invasion of tumor cells into healthy tissue. 
FIG. 12 shows a Western Blot analysis using 10 µg total 45 
protein obtained from Untreated-IE- (left) and nano-IE 
treated-IE+ (right) animals showing differences in cell pro-
liferation and migration marker protein expression. 
FIG. 13 is a chart showing cell viability as measured 
through an in vitro cell proliferation assay (cell viability as 
indicated through absorbance over time (hours)). Co-encap- 50 
sulated IE+DOX was as cytotoxic as liposomal DOX alone or 
liposomal DOX in conjunction with liposomal IE. Liposomal 
IE (which has a method of action to halt cellular invasion 
rather than serving as a cytotoxic agent) served as a control. 
FIG. 14 is a chart showing the plasma clearance of free 55 
imipramine blue ("IE") versus nanoencapsulated imipramine 
blue ("Nano-IE"), in terms of plasma IE concentration (mg/ 
ml) over time after injection (h). 
FIG. lS is a chart showing the in vivo survival time after 
implantation (days) with treatment with saline control (sa- 60 
line) or imipramine blue ("IE"). 
DETAILED DESCRIPTION 
The liposomal formulations and their use in treating inva- 65 
sive cancers, such as gliomas, will be better understood with 
reference to the following detailed description. 
4 
Imipramine Blue 
The anti-cancer properties of imipramine blue are dis-
closed in PCT/US08/88495. The activity of imipramine blue 
against cancer cells is believed to be due to its ability to inhibit 
various Nox enzymes, and/or inhibit the production of reac-
tive oxygen species (ROS). The ability of imipramine blue to 
inhibit the invasiveness of particularly aggressive and inva-
sive tumors, such as gliomas, such as glioblastoma multi-
forme (also known as GBM, or malignant glioma) has not 
previously been reported. Imipramine blue is also able to 
inhibit the invasiveness of these tumors at concentrations 
below which it is cytotoxic. 
Imipramine Blue has the formula: 
A resonance form of this structure is shown below: 
N(Et)2 
The compound is present in a salt form (e.g., as pharma-
ceutically acceptable salts). Examples of suitable pharmaceu-
tically acceptable salts include inorganic acid addition salts 
such as sulfate, phosphate, and nitrate; organic acid addition 
salts such as acetate, galactarate, propionate, succinate, lac-
tate, glycolate, malate, tartrate, citrate, maleate, fumarate, 
methanesulfonate, p-toluenesulfonate, and ascorbate; salts 
with an acidic amino acid such as aspartate and glutamate; 
alkali metal salts such as sodium and potassium; alkaline 
earth metal salts such as magnesium and calcium; annnonium 
salt; organic basic salts such as trimethylamine, triethy-
lamine, pyridine, picoline, dicyclohexylamine, and N,N'-
dibenzylethylenediamine; and salts with a basic amino acid 
such as lysine and arginine. The salts can be in some cases 
US 9,220,682 B2 
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hydrates or ethanol solvates. The stoichiometry of the salt will 
vary with the nature of the components. 
Prodrug forms of imipramine blue can also be used. One 
such prodrug forms is that in which the iminium group is 
reduced, for example, with sodium cyanoborohydride. This 
prodrug can readily be reoxidized into the parent compound, 
and may offer various advantages over imipramine blue. That 
is, the prodrug form is less colored and more lipophilic (be-
cause the iminium salt is reduced to an amine). The com-
pound can be more easily taken up by cells than imipramine 
blue, and may be less irritating in vivo. In tumors/blood 
vessels with high levels of superoxide/hydrogen peroxide, the 
prodrug can be readily oxidized to imipramine blue within the 
cell. 
One or more of the amine groups can be converted to amide 
groups, which, upon hydrolysis, yield the amines, which can 
6 
lipids, preferably ones that are saturated, and have a carbon 
chain length of at least 16 carbons, preferably between 16 and 
18 carbons. Distearoylphosphatidyl choline (DSPC) is a pre-
ferred phospholipid. 
Cholesterol helps to stabilize the liposomes, and is prefer-
ably added in a sufficient amount to provide liposome stabil-
ity. 
Preparation of Liposomes 
The liposomes which are used in the invention are small 
10 unilamellar liposomes of a size of less than 200 nm, prefer-
ably having a diameter of from about 50 to about 160 nm. As 
noted above, the vesicles are preferably comprised of chemi-
cally pure synthetic phospholipids having saturated aliphatic 
side chains and most preferably are prepared from phospho-
15 lipids such as distearoyl phosphatidylcholine. Cholesterol is 
advantageously incorporated into the liposomes to increase 
the stability of the vesicles which are used in the disclosed 
process. be oxidized to form the active compounds. Where the amide group is a trichloroacetyl amide group, the hydrolysis also 
produces the trichloroacetate salt, which can fight cancer via 
20 
a different route than the active compounds (thus forming an 
in-situ drug cocktail from a single prodrug. Conditions for 
forming amides from amines and acids, or acid halides/anhy-
drides, are well known to those of skill in the art and need not 
The liposomes preferably include imipramine blue, or a 
pharmaceutically acceptable salt thereof, but can optionally 
or additionally include other triaryl methane anti-tumor 
agents, such as those described in PCT/US08/88495, the con-
tents of which are hereby incorporated by reference. 
The liposomes can be prepared by dissolving the phospho-be repeated here. 
Synthesis of Imipramine Blue 
Imipramine blue can be synthesized by reacting 1m1-
pramine with Mischler' s Ketone and an acid like phosphorus 
oxychloride (POCl3 ), as shown below: 
+N(Et)2 
(Et2)N 
Liposome Components 
imiprarnine 
POCl3 
+N(Et)i Ct 
N 
(Me)iN I 
There is a relatively high liver clearance of liposomes, 
which is not surprising, as this organ is one of the major sites 
of blood borne particulate removal. Accordingly, it can be 
advantageous to include one or more pegylated phospholip-
ids in the liposomes. 
It can also be advantageous that the liposomes have a 
melting point above body temperature (i.e., above 37° C.). 
For this reason, it can be advantageous to use pure phospho-
25 lipid and cholesterol in an appropriate organic solvent, such 
as chloroform, and evaporating the solvent to form a lipid 
film. If an ionophore is employed to load the imipramine blue, 
and/or a further diagnostic or therapeutic agent, into the lipo-
somes, this compound may be added to the lipid solution 
30 before evaporation. 
The dried lipid film is then rehydrated in an appropriate 
aqueous phase, such as phosphate-buffered saline or other 
physiologically appropriate solution. Water-soluble drugs or 
therapeutic agents may be contained in the hydrating solu-
35 tion, although if remote loading is desired a loading agent 
such as a chelating agent described above may be added to the 
hydrating solution to be encapsulated within the inner aque-
ous space of the liposome. 
Upon the addition of the hydrating solution, liposomes of 
40 varying size spontaneously form and encapsulate a portion of 
the aqueous phase. Thereafter, the liposomes and suspending 
aqueous solution are subjected to a shear force such as extru-
sion, sonication, or processing through a homogenizer 
accordingtothemethoddescribedin U.S. Pat. No. 4,753,788; 
45 to produce vesicles within the specified size. 
50 
55 
The liposomes can then be processed to remove undesir-
able compounds from the suspending solution, for example 
the chelating agent or unencapsulated drug, which may be 
accomplished through processes such as gel chromatography 
or ultrafiltration. 
If necessary, the product is then concentrated to remove 
excess buffer solution. Since the liposomes are smaller in size 
than 0.2 micron, they can be passed through a sterile 0.22 
micron filter to remove any microorganisms which may be 
present in the suspension. Thereafter, the liposomes can be 
filled into sterilized glass containers and stoppered with a 
sterilized elastomer closure. 
The liposomal compositions are ideally administered via 
intravenous injection, though can optionally be administered 
60 intracerebroventricularly. Suitable carriers for injection are 
well known to those of skill in the art, and include 5% dex-
trose solutions, saline, and phosphate buffered saline. 
Ideally, before injection, the liposomal suspension is tested 
to confirm that the liposomes have not aggregated, as liposo-
65 ma! aggregation can be problematic. 
In one embodiment, the liposomes are stored as a dry 
powder before use, for example, by freeze-drying a Ii po some 
US 9,220,682 B2 
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suspension, and reconstituted innnediately before use. 
Reconstitution of dried liposomes, and additional compo-
nents used to stabilize liposomes during the drying process, 
are well known to those of skill in the art. 
Combination Therapy 
8 
Imipramine blue can be combined with lovastatin, a HMG-
CoA reductase inhibitor, and butyrate, an inducer of apopto-
sis in the Lewis lung carcinoma model in mice, can potentiate 
antitumor effects (Giermasz, A., et al., Int. J. Cancer 97:746-
750 (2002)). Examples of known HMG-CoA reductase 
inhibitors, which can be used for combination therapy 
include, but are not limited to, lovastatin, simvastatin, prav-
astatin, fluvastatin, atorvastatin and cerivastatin, and pharma-
ceutically acceptable salts thereof. 
Certain HIV protease inhibitors, such as indinavir or 
saquinavir, have potent anti-angiogenic activities and pro-
mote regression of Kaposi sarcoma (Sgadari, C., et al., Nat. 
Med. 8: 225-23 2 (2002) ). Accordingly (in addition to forming 
triphenyl methane analogues of these compounds), the triph-
The combination therapy may be administered as (a) a 
single pharmaceutical composition which comprises imi-
pramine blue and at least one additional pharmaceutical agent 
described herein, and a pharmaceutically acceptable excipi-
ent, diluent, or carrier; or (b) two separate pharmaceutical 10 
compositions comprising (i) a first composition comprising 
imipramine blue and a pharmaceutically acceptable excipi-
ent, diluent, or carrier, and (ii) a second composition com-
prising at least one additional pharmaceutical agent described 
herein and a pharmaceutically acceptable excipient, diluent, 
15 enyl methane analogues can be combined with HIV protease 
inhibitors, or a pharmaceutically acceptable salt of said agent. 
Representative HIV protease inhibitors include, but are not 
limited to, amprenavir, abacavir, CGP-73547, CGP-61755, 
DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, 
or carrier. The pharmaceutical compositions can be adminis-
tered simultaneously or sequentially and in any order. 
In use in treating or preventing cancer, the imipramine blue 
described herein can be administered together with at least 
one other chemotherapeutic agent as part of a unitary phar-
maceutical composition. Alternatively, the imipramine blue 
can be administered apart from the other anticancer chemo-
therapeutic agent. In this embodiment, the imipramine blue 
and the at least one other anticancer chemotherapeutic agent 
are administered substantially simultaneously, i.e. the com-
pounds are administered at the same time or one after the 
other, so long as the compounds reach therapeutic levels for a 
period of time in the blood. 
20 saquinavir, ABT-378, AG 1776, and BMS-232,632. 
Synthetic retinoids, such as fenretinide (N-( 4-hydroxyphe-
nyl)retinamide, 4HPR), can have good activity in combina-
tion with other chemotherapeutic agents, such as cisplatin, 
etoposide or paclitaxel in small-cell lung cancer cell lines 
25 (Kalemkerian, G. P., et al., Cancer Chemother. Pharmacol. 
43:145-150 (1999)). 4HPR also was reported to have good 
activity in combination with gannna-radiation on bladder 
cancer cell lines (Zou, C., et al., Int. J. Oneal. 13:1037-1041 
(1998)). Representative retinoids and synthetic retinoids 
Combination therapy involves administering imipramine 
blue, or a pharmaceutically acceptable salt or prodrug 
thereof, in combination with at least one anti-cancer chemo-
therapeutic agent, ideally one which functions by a different 
mechanism (i.e., VEGF inhibitors, alkylating agents, and the 
like). 
30 include, but are not limited to, bexarotene, tretinoin, 13-cis-
retinoic acid, 9-cis-retinoic acid, .alpha.-difluoromethylorni-
thine, ILX23-7553, fenretinide, and N-4-carboxyphenyl reti-
namide. 
Proteasome inhibitors, such as lactacystin, exert anti-tu-
35 mor activity in vivo and in tumor cells in vitro, including those 
resistant to conventional chemotherapeutic agents. By inhib-
iting NF-kappaB transcriptional activity, proteasome inhibi-
tors may also prevent angiogenesis and metastasis in vivo and 
Examples of known anticancer agents which can be used 
for combination therapy include, but are not limited to alky-
lating agents, such as busulfan, cis-platin, mitomycin C, and 
carboplatin; antimitotic agents, such as colchicine, vinblas-
tine, paclitaxel, and docetaxel; topo I inhibitors, such as 40 
camptothecin and topotecan; topo II inhibitors, such as doxo-
rubicin and etoposide; RNA/DNA antimetabolites, such as 
5-azacytidine, 5-fluorouracil and methotrexate; DNA antime-
tabolites, such as 5-fluoro-2'-deoxy-uridine, ara-C, hydrox-
yurea and thioguanine; and antibodies, such as Herceptin® 45 
and Rituxan®. Other known anti-cancer agents, which can be 
used for combination therapy, include arsenic trioxide, gam-
citabine, melphalan, chlorambucil, cyclophosamide, ifosfa-
mide, vincristine, mitoguazone, epirubicin, aclarubicin, bleo-
mycin, mitoxantrone, elliptinium, fludarabine, octreotide, 50 
retinoic acid, tamoxifen and alanosine. Other classes of anti-
cancer compounds that can be used in combination with the 
triphenyl methane analogues are described below. 
Imipramine blue can be combined with alpha-1-adreno-
ceptor antagonists, such as doxazosin, terazosin, and tamsu- 55 
lo sin, which can inhibit the growth of prostate cancer cell via 
induction of apoptosis (Kyprianou, N., et al., Cancer Res 
60:4550-4555, (2000)). 
Sigma-2 receptors are expressed in high densities in a 
variety of tumor cell types (Vilner, B. J., eta!., Cancer Res. 55: 60 
408-413 (1995)) and sigma-2 receptor agonists, such as 
CB-64D, CB-184 and haloperidol, activate a novel apoptotic 
pathway and potentiate antineoplastic drugs in breast tumor 
cell lines. (Kyprianou, N., et al., Cancer Res. 62:313-322 
(2002) ). Accordingly, the triphenyl methane analogues can be 65 
combined with at least one known sigma-2 receptor agonists, 
or a pharmaceutically acceptable salt of said agent. 
further increase the sensitivity of cancer cells to apoptosis 
(Almond, J.B., et al., Leukemia 16:433-443 (2002)). Repre-
sentative proteasome inhibitors include, but are not limited to, 
lactacystin, MG-132, and PS-341. 
Tyrosine kinase inhibitors, such as STI571 (Imatinib mesi-
late, Gleevec®), have potent synergetic effects in combina-
tion with other anti-leukemic agents, such as etoposide (Liu, 
W. M., et al. Br. J. Cancer 86:1472-1478 (2002)). Represen-
tative tyrosine kinase inhibitors include, but are not limited to, 
Gleevec®, ZD1839 (Iressa®), SH268, genistein, CEP2563, 
SU6668, SUl 1248, and EMD121974. 
Prenyl-protein transferase inhibitors, such as farnesyl pro-
tein transferase inhibitor Rl 15777, possess anti tumor activity 
against human breast cancer (Kelland, L. R., et. al., Clin. 
Cancer Res. 7:3544-3550 (2001)). Synergy of the protein 
farnesyltransferase inhibitor SCH66336 and cisplatin in 
human cancer cell lines also has been reported (Adjei, A. A., 
eta!., Clin. Cancer. Res. 7:1438-1445 (2001)). Prenyl-protein 
transferase inhibitors, including farnesyl protein transferase 
inhibitor, inhibitors of geranylgeranyl-protein transferase 
type I (GGPTase-I) and geranylgeranyl-protein transferase 
type-II, or a pharmaceutically acceptable salt of said agent, 
can be used in combination with the triphenyl methane ana-
logues described herein. Examples of known prenylprotein 
transferase inhibitors include, but are not limited to, 
Rl 15777, SCH66336, L-778,123, BAL9611 and TAN-1813. 
Cyclin-dependent kinase (CDK) inhibitors, such as fla-
vopiridol, have potent, often synergetic, effects in combina-
tion with other anticancer agents, such as CPT-11, a DNA 
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topoisomerase I inhibitor in human colon cancer cells (Mot-
wani, M., et al., Clin. Cancer Res. 7:4209-4219, (2001)). 
Representative cyclin-dependent kinase inhibitors include, 
but are not limited to, flavopiridol, UCN-01, roscovitine and 
olomoucine. 
Certain COX-2 inhibitors are known to block angiogen-
esis, suppress solid tumor metastases, and slow the growth of 
implanted gastrointestinal cancer cells (Blanke, C. D., Oncol-
ogy (Hunting) 16 (No. 4 Suppl. 3):17-21 (2002)). Represen-
tative COX-2 inhibitors include, but are not limited to, cele-
coxib, valecoxib, and rofecoxib. 
IKB-a phosphorylation inhibitors, such as BAY-11-7082 
(an irreversible inhibitor ofIKB-a phosphorylation) are also 
known to induce apoptosis, or to enhance the effectiveness of 
other agents at inducing apoptosis. These inhibitors can also 
be used in combination with the compounds described herein. 
Any of the above-mentioned compounds can be used in 
combination therapy with the imipramine blue. 
The imipramine blue can also be used in conjunction with 
surgical tumor removal, by administering the compounds 
before and/or after surgery, and in conjunction with radiation 
therapy, by administering the compounds before, during, and/ 
or after radiation therapy. 
10 
phore are employed for loading external cations for radiola-
belling into the vesicles. The preferred ionophore is A23187, 
but other useful ionophores are polyethers such as lasalocid 
A(X-537 A) and 5-bromo derivatives oflasalocid; cyclic dep-
sipeptides such as beauvericin; and cyclic peptides such as 
valinomylin. The chelating agent is preferably nitriloacetic 
acid (NTA) although other chelators may also be used. 
Methods of Using the Compounds and/or Pharmaceutical 
Compositions 
10 The pharmaceutical compositions described herein can be 
used to treat cancers, preferably, but not limited to, invasive 
cancers such as gliomas. 
The cancers include, but are not limited to, those in which 
15 one of the Nox enzymes is present in elevated concentrations (i.e., Nox 1, Nox 4, and the like), or those in which cancer 
growth is mediated by reactive oxygen species (ROS). 
Representative disorders that can be treated include neo-
plasms, such as hemangiomas, and malignant tumors, for 
20 example, those which arise in the setting of autocrine loops 
involving vascular endothelial growth factor (VEGF) and its 
major mitogenic receptor vascular endothelial growth factor 
receptor 2. Representative malignant tumors include malig-
nant endothelial tumors such as melanoma. The appropriate dose of the imipramine blue and, option-
ally, additional agents is that amount effective to prevent 25 
occurrence of the symptoms of the disorder or to treat some 
symptoms of the disorder from which the patient suffers. By 
"effective amount'', "therapeutic amount" or "effective dose" 
Representative malignant tumors include malignant endot-
helial tumors such as melanoma. Additional cancers that can 
be treated include, but not limited to human sarcomas and 
carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, 
chondrosarcoma, osteogenic sarcoma, chordoma, angiosar-
coma, endotheliosarcoma, lymphangiosarcoma, lymphan-
gioendotheliosarcoma, synovioma, mesothelioma, Ewing's 
is meant that amount sufficient to elicit the desired pharma-
cological or therapeutic effects, thus resulting in effective 30 
prevention or treatment of the disorder. 
When treating cancers, an effective amount of the imi-
pramine blue is an amount sufficient to suppress the growth of 
the tumor(s), and, ideally, is a sufficient amount to shrink the 
tumor, and, more ideally, to destroy the tumor, inhibit its 35 
invasiveness, and/or inhibit its metastasis. Cancer can be pre-
vented, either initially, or from re-occurring, by administering 
the compounds described herein in a prophylactic manner. 
Preferably, the effective amount is sufficient to obtain the 
desired result, but insufficient to cause appreciable side 40 
effects. 
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carci-
noma, pancreatic cancer, breast cancer, ovarian cancer, pros-
tate cancer, squamous cell carcinoma, basal cell carcinoma, 
adenocarcinoma, sweat gland carcinoma, sebaceous gland 
carcinoma, papillary carcinoma, papillary adenocarcinomas, 
cystadenocarcinoma, medullary carcinoma, bronchogenic 
carcinoma, renal cell carcinoma, hepatoma, bile duct carci-
noma, choriocarcinoma, seminoma, embryonal carcinoma, 
Wilms' tumor, cervical cancer, testicular tumor, lung carci-
noma, small cell lung carcinoma, bladder carcinoma, epithe-
The effective dose can vary, depending upon factors such 
as the condition of the patient, the severity of the cancer, and 
the manner in which the pharmaceutical composition is 
administered. The effective dose of compounds will of course 
differ from patient to patient, but in general includes amounts 
starting where desired therapeutic effects occur but below the 
amount where significant side effects are observed. 
The compounds, when employed in effective amounts in 
accordance with the method described herein, are selective to 
certain cancer cells, but do not significantly affect normal 
cells. 
For human patients, the effective dose of typical com-
pounds generally requires administering the compound in an 
amount of at least about 1, often at least about 10, and fre-
quently at least about 25 µg/24 hr/patient. The effective dose 
generally does not exceed about 500, often does not exceed 
about 400, and frequently does not exceed about 300 µg/24 
hr/patient. In addition, administration of the effective dose is 
such that the concentration of the compound within the 
plasma of the patient normally does not exceed 500 ng/mL 
and frequently does not exceed 100 ng/mL. 
Diagnostic Agents 
A wide variety of diagnostic agents may be incorporated in 
the inner aqueous space or the lipid bilayer of the liposomes 
by methods which will be apparent to one of skill in the art. In 
the following examples a chelating compound and an iono-
lial carcinoma, glioma, astrocytoma, medulloblastoma, cran-
iopharyngioma, ependymoma, pinealoma, 
hemangioblastoma, acoustic neuroma, oligodendroglioma, 
45 meningioma, melanoma, neuroblastoma, retinoblastoma; 
leukemias, e.g., plasma cell leukemia, acute lymphocytic leu-
kemia, acute myelocytic leukemia (myeloblastic, promyelo-
cytic, myelomonocytic, monocytic and erythroleukemia); 
chronic leukemia (chronic myelocytic (granulocytic) leuke-
50 mia and chronic lymphocytic leukemia); and polycythemia 
vera, lymphoma (Hodgkin's disease and non-Hodgkin's dis-
ease), including NF-KB mutant and Velcade Resistant lym-
phoma cells, multiple myeloma, PI3 kinase deficient 
myeloma, Waldenstrom's macroglobulinemia, and heavy 
55 chain disease, and malignant forms of these cancers. Addi-
tionally, the compounds can be used in assays involving lym-
phoblastoid and EBY positive cells. 
In one embodiment, the cancer is melanoma, rectal carci-
noma, colon carcinoma, breast carcinoma, ovarian carci-
60 noma, small cell lung carcinoma, colon carcinoma, chronic 
lymphocytic carcinoma, hairy cell leukemia, esophageal car-
cinoma, prostate carcinoma, breast cancer, myeloma, or lym-
phoma. It is believed that these cancers have circulating levels 
oftNOX (which may include Nox4 or other Nox enzymes) 
65 present in the sera of patients suffering from the cancer (see, 
for example, U.S. Pat. No. 5,605,810, which is hereby incor-
porated by reference in its entirety). 
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In some embodiments, the patient already has cancer and is 
undergoing treatment for the cancer, and may or may not have 
tumor metastasis (i.e., secondary cancer). 
In other embodiments, the compositions are active at inhib-
iting hypoxia-inducible factor HIF2a expression, and this 
activity aids in the treatment of tumors resistant to standard 
chemoradiotherapy. Hypoxia-inducible factor HIF2alpha 
(HIFalphas) regulates the expression of a variety of genes 
encoding proteins related to angiogenesis and to anaerobic 
metabolism of cells exposed to hypoxic stress (Koukourakis 10 
et al., Int J Radiat Oneal Biol Phys. 2002 Aug. 1;53(5):1192-
202.) HIF2a overexpression is significantly associated with 
high microvessel density (p=0.02, respectively) and with 
VEGF expression (p=0.005), and VEGF/KDR-activated 15 
tumor vasculature is more frequent in HIF2a-overexpressing 
tumors (p=0.02). High HIF2a levels have been associated 
with incomplete response to chemoradiation (p=0.02, respec-
tively), and overexpression of HIF2a is related to locally 
aggressive behavior, intensification of angiogenesis, and 20 
resistance to carboplatin chemoradiotherapy. 
As discussed in PCT/US08/88495, imipramine blue was 
evaluated in a HIF2a expression model, and was shown to 
inhibit around 90% of the HIF2a expression. In this expres-
sion model, WM35 PKB cells are exposed to 5 micromolar of 25 
test compounds for 24 hours. At the end of this period, cells 
are harvested for RNA, which is then reverse transcribed into 
cDNA, and levels of HIF2a message are quantified using 
quantitative RT-PCR and corrected for a housekeeping RNA 
message. As demonstrated using this assay, these compounds 30 
can act as direct NADPH oxidase inhibitors, as well as super-
oxide scavengers that absorb superoxide produced by defec-
tive mitochondria or other cellular processes. 
12 
like IB, triaryl methanes disclosed in PCT/US08/88495, and 
IB showed the highest anti-invasive properties of the triaryl 
methanes tested. 
One compound, IB was determined to be anti-invasive 
while not cytotoxic and not antiproliferative. It also is benign 
to astrocyte co-culture making it safer for delivery to the brain 
(FIG. 3a ). The compound is blue in color with an absorbance 
at 610 nm making it easily assayable. This compound offers 
dose-dependent anti-invasive response against malignant 
glioma cell line RT2A in culture (FIG. 3b ). At concentrations 
above 20 µg/ml, IB was cytotoxic to cancer and not just 
anti-invasive. 
Some of the compounds are proprietary compounds, so 
their identity is not provided herein. However, a listing of the 
non-proprietary compounds is provided below. Where the 
structure is well known, it is not provided, and where the 
structure is not well known, it is provided at the end of the list. 
1. Honokiol 
2. Honokiol Diketone Fulvene 
3. Magnolol 
4. Protected Magnolol (i.e., wherein the hydroxy groups are 
protected with protecting groups) 
5. GdCu3 
6. Honokiol Diepoxides (i.e., wherein the double bonds in 
honokiol are replaced with epoxide groups) 
7. Thiobendazole Blue-the product of the reaction of 
thiobendazole and Mischler's ketone under reactions con-
ditions described in PCT/US08/88495 
The cancer may be manifested in the form of a tumor, such 
as a tumor of epithelial tissue, lymphoid tissue, connective 
tissue, bone, or central nervous system. 
35 8. Carbazole Blue 
The compositions can also be used as adjunct therapy in 
combination with existing therapies in the management of the 
aforementioned types of cancers. In such situations, it is 
preferably to administer the active ingredients to in a manner 40 
that optimizes effects upon cancer cells, including drug resis-
tant cancer cells, while minimizing effects upon normal cell 
types. While this is primarily accomplished by virtue of the 
behavior of the compounds themselves, this can also be 
accomplished by targeted drug delivery and/or by adjusting 45 
the dosage such that a desired effect is obtained without 
meeting the threshold dosage required to achieve significant 
side effects. 
The present invention will be better understood with refer-
ence to the following non-limiting examples. 
EXAMPLE 1 
In Vitro Compound Screen 
50 
55 
An aggressive rat astrocytoma cell line, RT2, was main-
tained in vitro. This cell line was used to test 24 compounds at 
varying concentrations in cytotoxicity and proliferation 
assays using CCK8 (Dojindo ), a tetrazolium salt based assay. 
Compounds without detrimental effects on viability and 60 
growth were tested using the Boyden chamber invasion assay 
at 48 hours. Compounds were also tested for viability against 
astrocyte cultures using CCK8. Of these compounds, several 
were identified as anti-invasive. However, several compounds 65 
were toxic to astrocytes in culture and several were cytotoxic 
and not in fact anti-invasive. Several of these compounds are, 
9. Imipramine Blue 
10. Honokiol in which one or both hydroxy groups have been 
replaced by dichloroacetate and trichloroacetate esters 
11. DDT Black 
12. Tetrafluoro Brilliant Green 
13. The triaryl methane resulting from the reaction of Mis-
chler' s ketone and Promethazine under conditions 
described in in PCT/US08/88495 
14. Saccharine Blue (structures shown below) 
15. Thymol Green-the triaryl methane resulting from the 
reaction of Mischler' s ketone and thymol under conditions 
described in in PCT/US08/88495, believed to have the 
structure shown below. 
16. Geldanamycin 
N(Et)i 
Cl N(Et)i 
DDT Black 
13 
-continued 
Carbazole Blue 
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Geldanamycin 
OCONH2 
():~\. rs /---~\) 
Thiobendazole (thiobendazole blue is obtained by reacting 
25 this compound and Mischler's ketone under conditions as 
described in PCT/US08/88495). 
30 
EXAMPLE2 
Preparation and Evaluation of Liposomes Containing 
Imipramine Blue 
This example evaluated the effectiveness ofIB-containing 
35 liposomes in a live rat model. 
Nanocarrier Synthesis: 
Liposomes were made from DSPC (85 mo! % ), DSPE-
PEG (5 mo!%, Avanti Polar Lipids)), and cholesterol (10 mo! 
%, Sigma) by dissolving the lipids and 2 mg/ml of IB in 
40 ethanol. The solution was hydrated using phosphate buffered 
saline at 70° C. to yield liposomes. Liposomes were extruded 
to a size of 160 nm as assessed by dynamic light scattering. 
Unbound drug was removed via sepharose column separation 
and then diafiltrated to a final IB concentration of3 .5 mg/ml. 
45 In Vivo Animal Studies: 
Saccharine blue-the reaction product of saccharine with 
Mischler' s Ketone includes one or both of these compounds 50 
For tumor inoculation, 8-10 week old week old Fischer 344 
rats were anesthetized using 2-3% Isoflurane inhalant. A 1 cm 
incision to the skull was made and a 2 mm burr hole was 
drilled 2 mm lateral and 6 mm posterior to bregma. 250,000 
cells were injected in 10 µI ofLeibovitz media over a period 
of 10 minutes using a Hamilton syringe. The hole was filled 
+N(Et)i 
OH 
Thymol green 
with bone wax and the wound closed. 
On days 4 and 7 of tumor growth, 16 mg/kg (IB concen-
55 tration) of IB-liposomes were injected via the tail vein. On 
Day 11 following tumor inoculation animals were sacrificed 
by intracardial perfusion. Brains were removed, photo-
graphed, fixed, embedded in OCT and sectioned. Slides were 
collected, stained using DAPI and imaged. Image analysis 
60 was conducted in a blinded fashion to quantify invasiveness. 
The results are shown in FIGS. 3a and 3b, which show 
tumor progression at Day 11 in Fischer 344 rats using DAPI 
stain for cell nuclei. As shown in FIG. 3a, untreated tumor 
shows chaotic borders nad infiltrative tumor cells, whereas 
65 FIG. 3b shows that IB-liposome treated tumors show a more 
encapsulated morphology with well-defined borders between 
the tumor and the healthy brain. 
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Results: 
We have identified imipramine blue as a potent anti-inva-
sive agent for glioma, and have efficiently encapsulated IB in 
liposomal nanocarriers. In preliminary studies, IB-liposomes 
significantly impacted glioma invasion in vivo. 
Conclusions: 
16 
saline and then 4% paraformaldehyde. Brains were removed, 
fixed, embedded and sectioned through the tumor. Slides 
were collected, stained using DAPI, and imaged using Neu-
rolucida. 
Animals were treated with encapsulated IB at two time 
points after tumor inoculation. The results of the treatment on 
day 11 revealed a change in the phenotype of the tumor 
between treated and untreated tumors in terms of invasion 
into surrounding brain tissue. FIG. 6a shows a photograph of 
In this study, we have shown use of a novel anti-invasive 
compound, imipramine blue, to inhibit invasion in vitro and 
in vivo when delivered in nanocarriers. Therefore, anti-inva-
sive compounds may be used for treatment of invasive tumors 
in conjunction with cytotoxic therapy or surgery. The imi-
pramine blue can be co-encapsulated and delivered with com-
mon chemotherapeutics and used in conjunction with tumor 
resection. 
10 an untreated tumor, with green being healthy tumor cells and 
blue indicating cell nuclei for unhealthy tumor cells and nor-
mal brain structures. FIG. 6b shows a photograph of a treated 
tumor (smaller in size than the untreated tumor), which was 
similarly stained, and which showed more unhealthy tumor 
15 cells and a more of a contained (i.e., less invasive) structure. 
EXAMPLE3 
Further Evaluation of IE-Containing Liposomes 
This example evaluated the effectiveness ofIB-containing 20 
liposomes in a live rat model, at a slightly higher dosage ofIB 
within the liposomes than was present in Example 2. 
Nanocarrier Synthesis: 
Liposomes were made from DSPC (85 mo! % ), DSPE-
PEG ( 5 mo!%, Avanti Polar Lipids)), and cholesterol (10 mo! 25 
%, Sigma) by dissolving the lipids and IB in ethanol. The 
solution was hydrated using phosphate buffered saline at 70° 
C. to yield liposomes. Liposomes were extruded to a size of 
160 nm as assessed by dynamic light scattering. Unbound 
drug was removed via sepharose column separation and then 30 
diafiltrated to a final IB concentration of 7-8 mg/ml. 
Pharmacokinetics and Biodistribution Studies: 
Animals were injected via tail vein with 20 mg/kg liposo-
mal or free IB. Orbital blood draws were performed at inter-
vals and blood collected, centrifuged, and serum read at 610 35 
nm absorbance for pharmacokinetics. For biodistribution, 
animals were perfused with saline, organs collected, homog-
enized, and drug extracted with DMSO and read at 610 nm 
absorbance for pharmacokinetics. For biodistribution, ani-
mals were perfused with saline, organs collected, homog- 40 
enized, and drug extracted with DMSO and read at 610 nm 
absorbance. 
EXAMPLE4 
In Vivo and In Vitro Evaluation of Imipramine Blue 
("IB") and Combination of IB and Doxorubicin 
("DOX") 
According to the National Cancer Institute, brain tumors 
are the leading cause of solid tumor cancer death in children. 
Glioblastoma Multiforme (GBM) is a highly infiltrative and 
lethal form of brain tumor. These tumors are characterized as 
being unresponsive to traditional cancer treatments, and 
result in poor prognosis and survival due to their invasive and 
diffusive nature. 
Common treatments focus on reducing the bulk of the 
tumor via radiation, chemotherapy, and surgical resection, 
which leads to residual tumor at the site and recurrence. This 
example evaluated a new strategy for treatment, which 
focuses on inhibiting the invasion of these tumors, alone and 
in conjunction with common therapeutic strategies. While not 
wishing to be bound to a particular theory, it is believed that if 
the tumor can be effectively contained via treatment, then it 
should be more responsive to chemotherapeutics, resection, 
and radiation, and thus yield a better prognosis after treat-
ment. 
The compound imipramine blue ("IB") is a novel com-
pound that inhibits invasion of glioblastoma in vitro and 
shows promise in vivo in a rat model of GBM. Using this 
compound as a chemopreventive agent to inhibit progression 
An invasion assay was performed at 24 hours. The encap-
sulated formulation was compared to tree drug in vitro and 
was still active as an anti-invasive agent. Encapsulation of the 
compound in liposomes is reproducible and consistent 
between batched. The data is shown in FIG. 4, where the 
control shows 100 percent invasion, the liposomal IB formu-
lation showed around 70% invasion, and free IB showed 
around 60% invasion. 
45 of lower grade gliomas to higher grade gliomas, as well as 
treatment of high grade gliomas, is a promising therapeutic 
alternative. 
The circulation time of the free imipramine blue was tested 
The use of an encapsulated anti-invasive agent alone, and 
in conjunction with common cancer therapy strategies, can 
50 yield a more promising prognosis in glioblastoma multiforme 
by affecting the phenotype of the tumor. The goal of this study 
was to determine the efficacy of the agent in vivo using a 
tumor targeted delivery system. To accomplish this goal, IB 
in a Cremaphor formulation similar to that of paclitaxel. The 
final half-life was around 11 minutes due to its quick absorp-
tion into body tissues. The drug was encapsulated in lipo-
somes, and hielded a half-life of21 hours and accumulation in 55 
the tumor. The data is shown in FIG. 5. 
was synthesized and characterized in vitro. Nanocarriers that 
deliver IB were prepared and characterized in vitro and in 
vivo assays, and part of the characterization included phar-
In Vivo Treatment with Imipramine Blue: 
All protocols were approved by the Georgia Institute of 
Technology Institutional Animal Use For tumor inoculation, 
12 week old Fischer 344 rats were anesthetized using 2-3% 
Isoflurane inhalant. A 1 cm incision to the skull was made and 
a 2 mm burr hole was drilled 2 mm lateral and 6 mm posterior 
to bregma. 200,000 cells were injected in 10 µI ofLeibovitz 
media over a period of 10 minutes using a Hamilton syringe. 
On two days after inoculation, IB-liposome was delivered in 
saline via the tail vein. On Day 11 following tumor inocula-
tion, animals were sacrifieced by intracardial perfusion with 
macokinetics and biodistribution. The efficacy of a particular 
type of IB nanocarrier, a liposome, was evaluated in vivo, 
including an assessment of its effects on survival and pheno-
60 type. Co-encapsulated chemotherapeutic/anti-invasive nano-
carriers were prepared and characterized in vivo. 
Imipramine Blue Shows Promising Anti-Invasive Quali-
ties In Vitro. 
Pharmacokinetic studies on the alteration in bioavailability 
65 ofIB in vivo show an increase in half-life from 11 minutes to 
21 hours when liposomally encapsulated. Preliminary sur-
vival studies indicate that the drug slightly prolongs survival 
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of animals with the highly aggressive RT2 glioma model from 
the control time of 13.4 days to 14.9 days (n=6 per group, 
p=0.05). This increase in survival is minor, however, the 
change in phenotype of the tumor was promising. Further, in 
vitro studies looking at the effect of co-delivery of IB and 
Doxorubicin indicated a synergistic effect on cell death (FIG. 
7). Also, the liposomal IB was delivered via subcutaneous 
administration in rats and effectively traveled to the lymph 
nodes, indicating the possibility for delivery to other meta-
static cancers. These preliminary results are evidenced by the 10 
blue color of lymph nodes collected from animals treated 
with liposomal IB (FIG. 8). 
The ability of IB to impact invasion capability of glioma 
cells was tested further in vitro. Cells were treated for 24 15 
18 
end, invasion assays have been run on multiple human and rat 
glioma cell lines; including RT2A, C6, F98, and U87 (results 
not shown). 
In preparation for in vivo studies evaluating the effect ofIB 
in combination with chemotherapeutics (e.g., doxorubicin), 
nanocarrier formulations loaded with both IB and doxorubi-
cin were tested in vitro for their effect on cell viability. When 
formulating the coencapsulated liposomes, one goal was to 
determine whether it was possible to encapsulate a high 
enough concentration of each of the therapeutics, and also 
whether coencapsulation impacted potency of either compo-
nent. The coencapsulated liposomes also offer a two-pronged 
approach to tumor therapy-anti-invasion and cytotoxicity-
which produces better results than eithertreatment alone. The 
coencapsulated liposomes were found to be as cytotoxic as 
liposomal doxorubicin alone or liposomal doxorubicin 
(DOX) delivered in conjunction with liposomal IB as tested 
by an in vitro cell proliferation assay (the level of absorbance 
hours with either IB dissolved in ethanol or an equivalent 
volume of ethanol. FIGS. 9A and 9B demonstrate how IB 
alters the arrangement of the cytoskeleton of glioma cells, 
which will ultimately impede the ability of these cells to 
invade surrounding healthy tissues. 
In vivo studies were conducted on a rat RT2 glioma model 
to determine the effect of nano-IB on tumor invasion into 
surrounding tissue. Adult male rats were inoculated with 200 
20 indicates the number of viable cells). Thus, the co-encapsu-
lated liposomes encapsulated enough DOX for the doxorubi-
cin to retain its potency (FIG. 13). 
k RT2 astrocytoma cells into the posterior cortex via syringe. 
At 4 and 7 days after inoculation, nano-IB was delivered i.v. 25 
On day 11 after tumor inoculation, brains were sectioned and 
counterstained with DAPI for tumor visualization. The 
treated tumors were smaller, denser, and exhibited less inva-
sion than the untreated control tumors, indicating the anti-
invasive effect ofnano-IB (FIG.10). The tumor boundaries of 30 
H&E stained sections were visualized, and the treatellA and 
llB). 
In preparation for in vivo studies evaluating the effect ofIB 
in combination with chemotherapeutics ( doxorubicin), nano-
carrier formulations loaded with both IB and doxorubicin 35 
were prepared and optimized for in vivo delivery. Nano-IB 
was formulated in animonium sulfate, which was used to 
facilitate the remote loading of doxorubicin. Unencapsulated 
drugs were removed through column chromatography, and 
the nanocarriers were concentrated through diafiltration. Co- 40 
encapsulated nanocarriers were successfully produced, and 
loading of doxorubicin was optimized to reflect the appropri-
ate concentration desired for delivery in vivo (-6.9 mg IB/mg 
DOX). 
EXAMPLE 5 
Imipramine Blue Increases Survival Time in RT2 
Tumor-bearing Rats 
To determine how Imipramine Blue (IB) changes survival 
time, RT2 glioma bearing rats were given Imipramine Blue 
liposomes (Nano-IB) allowed to survive until signs of mor-
bidity were apparent. Animals were inoculated with tumor 
into the rear cortex via intracranial injection. On days 4 and 7 
after inoculation, Nano-IB or saline was delivered via the tail 
vein. Delivery ofNano-IB yielded a 12% increase in survival 
time that was statistically significant (p=0.037) from saline 
control treated tumor bearing animals. Results are shown in 
FIG. 14. 
EXAMPLE 6 
Encapsulation of Imipramine Blue in Liposomes 
Increases Circulation Half-Life 
Imipramine Blue liposomes were injected via the tail vein 
into adult male rats (non tumor-bearing). Blood samples were 
taken via the orbital cavity at different time points after drug 
administration, plasma separated and analyzed for IB content 
via absorbance readings on spectrophotometer. Measure-
ments for free IB were taken over the course of 1 hour at 
which point readings were below detectable range and for 
Nano-IB readings were taken for 52 hours. Results are below 
with curves fit to the data. Half-life ofIB once encapsulated 
was increased from 12 minutes to 18 hours yielding more 
A proposed mechanism of action was determined through 45 
microarray analysis and in vitro studies. To this end, it was 
determined that IB appears to have acted by altering the 
arrangement of the cytoskeleton. Western blot analysis was 
used to measure the presence of markers for proteins as indi-
cators of cell proliferation and migration. Western blot was 50 
performed on samples extracted from untreated and nano-IB 
treated rat brains. The blots showed marked differences in 
expression of cell proliferation and migration marker proteins 
between the two treatments. Nano-IB treated animals showed 
reduced expression of the cell proliferation and migration 
markers: Profilin-1 and Calgranulin-A, and of the GDP dis-
sociation inhibitor-RhoGDI, when compared to the untreated 
animals (FIG. 12). Profilin-1 is known to promote binding to 
actin monomers, which along with Calgranulin-A are known 
55 time for tumor accumulation and less non-specific compart-
mentalization. 
to be involved in promoting cell proliferation and differentia-
tion. RhoGDI prevents the dissociation ofGuanosine diphos-
phate (GDP) in exchange for Guanosine triphosphate (GTP) 
which is needed to activate RhoA, a cell proliferation inhibi-
tor. 
The following references related to various aspects of the 
working examples and/or to the background of the invention 
described herein. These references, and all other references 
60 cited herein, are hereby incorporated by reference for all 
purposes. 
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From this description the essential characteristics of the 
invention can be readily ascertained and, without departing 
from the spirit and scope thereof, the invention can be adapted 
20 
wherein the liposomes comprise cholesterol and chemi-
cally pure phospholipids that are essentially neutral and 
contain saturated fatty acids of between 16 and 18 car-
bon atoms. 
2. The composition of claim 1, wherein the liposomes have 
a size of from about 50 to about 160 nanometers. 
3. The composition of claim 1, wherein the phospholipids 
are synthetic phospholipids. 
4. The composition of claim 1, wherein the phospholipids 
comprise distearoylphosphatidyl choline. 
5. The composition of claim 1, wherein the phospholipids 
comprise a pegylated phospholipid. 
to various usages. Changes in form and substitution of 
equivalents are contemplated as circumstances may suggest 10 
or render expedient, and although specific terms have been 
employed herein, they are intended in a descriptive sense and 
not for purposes of limitation. 
The invention claimed is: 
1. A composition for treating tumors in a patient, compris-
ing unilamellar liposomes, of a size ofless than 200 nanom-
eters as assessed by dynamic light scattering and containing a 
therapeutic amount of imipramine blue, or a pharmaceuti-
cally-acceptable salt thereof, in a pharmaceutically-accept-
able carrier for intraveneous administration, 
6. The composition of claim 1, wherein the phospholipids 
15 comprise DSPC, DSPE-PEG, and cholesterol. 
7. The composition of claim 6, wherein the ratio ofDSPC/ 
DSPE-PEG/cholesterol is about 85%/about5%/about10%. 
8. The composition of claim 1, further comprising an anti-
tumor agent other than imipramine blue. 
* * * * * 
